HK1254154A1 - Tafia抑制劑與纖溶酶原激活劑的聯合 - Google Patents

Tafia抑制劑與纖溶酶原激活劑的聯合

Info

Publication number
HK1254154A1
HK1254154A1 HK18113228.7A HK18113228A HK1254154A1 HK 1254154 A1 HK1254154 A1 HK 1254154A1 HK 18113228 A HK18113228 A HK 18113228A HK 1254154 A1 HK1254154 A1 HK 1254154A1
Authority
HK
Hong Kong
Prior art keywords
combination
plasminogen activator
tafia inhibitor
tafia
inhibitor
Prior art date
Application number
HK18113228.7A
Other languages
English (en)
Inventor
Kengo Noguchi
Yusuke Ito
Naoko Edo
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of HK1254154A1 publication Critical patent/HK1254154A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HK18113228.7A 2015-06-17 2018-10-16 Tafia抑制劑與纖溶酶原激活劑的聯合 HK1254154A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2015121856 2015-06-17
PCT/JP2016/067963 WO2016204239A1 (ja) 2015-06-17 2016-06-16 ＴＡＦＩａ阻害剤とプラスミノーゲンアクチベータの組み合わせ

Publications (1)

Publication Number Publication Date
HK1254154A1 true HK1254154A1 (zh) 2019-07-12

Family

ID=57546091

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18113228.7A HK1254154A1 (zh) 2015-06-17 2018-10-16 Tafia抑制劑與纖溶酶原激活劑的聯合

Country Status (8)

Country Link
US (1) US10517850B2 (zh)
EP (2) EP3607947A1 (zh)
JP (1) JPWO2016204239A1 (zh)
KR (1) KR20180014730A (zh)
CN (1) CN107635556A (zh)
CA (1) CA2989767A1 (zh)
HK (1) HK1254154A1 (zh)
WO (1) WO2016204239A1 (zh)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012023412A2 (pt) * 2010-03-18 2018-05-08 Daiichi Sankyo Company, Limited composto, drogra farmacêutica, inibidor de tafia, promotor de fibrinólise, droga preventiva ou terapêutica, composição farmacêutica, e, uso de um composto.
PL2548871T3 (pl) * 2010-03-18 2017-12-29 Daiichi Sankyo Company, Limited Pochodne imidazolu podstawionego cykloalkilem

Also Published As

Publication number Publication date
CA2989767A1 (en) 2016-12-22
EP3311812A4 (en) 2018-12-26
US10517850B2 (en) 2019-12-31
EP3311812A1 (en) 2018-04-25
WO2016204239A1 (ja) 2016-12-22
US20180243268A1 (en) 2018-08-30
EP3607947A1 (en) 2020-02-12
KR20180014730A (ko) 2018-02-09
JPWO2016204239A1 (ja) 2018-04-05
CN107635556A (zh) 2018-01-26

Similar Documents

Publication Publication Date Title
IL259560A (en) Inhibitors of the menin-mll interaction
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
ZA201604272B (en) Inhibitors of glutaminase
ZA201700304B (en) Spirocycloheptanes as inhibitors of rock
IL259796A (en) Aza-benzimidazole inhibitors of pad4
GB201521059D0 (en) Inhibitors of metallo-beta-lactamases
EP3405477C0 (en) INHIBITORS OF TRANSGLUTAMINASE
PL3313833T3 (pl) Związki i ich zastosowanie w charakterze inhibitorów transferazy n-mirystoilu
HK1248684A1 (zh) Usp7抑制劑化合物及使用方法
GB201708457D0 (en) Inhibitors of metallo-beta-lactamases
GB201501004D0 (en) Inhibitors
HK1250926A1 (zh) 抑制劑及其應用
HK1254691A1 (zh) 新型凝血酶抑制劑
GB201708451D0 (en) Inhibitors of metallo-beta-lactamases
HK1254154A1 (zh) Tafia抑制劑與纖溶酶原激活劑的聯合
GB201520949D0 (en) Inhibitors
GB201521547D0 (en) New therapeutic uses of enzyme inhibitors
GB201521541D0 (en) New therapeutic uses of enzyme inhibitors
GB201505971D0 (en) Inhibitors and their uses
GB201505975D0 (en) Inhibitors and their uses
AU2015903172A0 (en) Inhibitors of necroptosis
AU2015900416A0 (en) Inhibitors of necroptosis
GB201421812D0 (en) New therapeutic uses of enzyme inhibitors
GB201410529D0 (en) New therapeutic uses of enzyme inhibitors